title: [Evaluation of surfactant administration in neonates with respiratory distress syndrome. III. The role of intra-uterine stimulation on lung maturity].
abstract: Prenatal corticosteroids and exogenous surfactant therapy independently reduce the adds of neonatal death by about 40%. It is not clear however if babies who develop RDS despite prenatal corticosteroid therapy behave differently when later given exogenous surfactant. This paper presents an evaluation of the outcome of babies treated with Curosurf (a porcine surfactant) for RDS depending upon whether they received prenatal corticosteroids (16 babies) or not (11 babies). Although not randomised these two groups of babies appear to be similar in respect of gestational age. However, lower mortality was found in the group treated with prenatal corticosteroids (12.5% vs. 27.2%).
authors.affiliation: Kliniki Neonatologii Instytutu Ginekologii i Połoznictwa Akademii Medycznej w Poznaniu.
authors.forename: J
authors.initials: J
authors.lastname: Gadzinowski
authors.forename: H
authors.initials: H
authors.lastname: Halliday
authors.forename: M
authors.initials: M
authors.lastname: Szymankiewicz
authors.forename: G
authors.initials: G
authors.lastname: Breborowicz
authors.forename: S
authors.initials: S
authors.lastname: Sackey
authors.forename: E
authors.initials: E
authors.lastname: Sobczak
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D001688:Biological Products; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010743:Phospholipids; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
chemical_list: D000305:Adrenal Cortex Hormones; D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa
vernacular_title: Ocena leczenia surfaktantem noworodków z zespołem zaburzeń oddychania. III. Rola wewnatrzmacicznej stymulacji dojrzałości płuc.